WHO emergency use listing – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Sun, 03 Aug 2025 05:14:44 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 Accelerated Pathways for Vaccine Approval https://www.clinicalstudies.in/accelerated-pathways-for-vaccine-approval/ Sun, 03 Aug 2025 05:14:44 +0000 https://www.clinicalstudies.in/accelerated-pathways-for-vaccine-approval/ Read More “Accelerated Pathways for Vaccine Approval” »

]]> Accelerated Pathways for Vaccine Approval

Navigating Accelerated Vaccine Approval Pathways Without Compromising Quality

Why Accelerated Pathways Exist—and When They’re Appropriate

Accelerated pathways exist to address serious, life-threatening, or public health emergency conditions where waiting for long, traditional development cycles would result in preventable morbidity and mortality. For vaccines, acceleration is justified when there is a significant unmet medical need (e.g., emerging pathogen, resurgence of a high-burden disease), a plausible immune mechanism of protection, and a coherent plan to verify clinical benefit post-authorization. The regulatory philosophy is not to “lower the bar,” but to shift what is known pre-authorization versus what is confirmed after launch, while maintaining GxP and benefit–risk safeguards.

In practice, sponsors request acceleration via formal programs (e.g., Fast Track, Breakthrough Therapy, Priority Review, PRIME, Conditional Marketing Authorization). These programs offer tools such as rolling reviews, frequent scientific advice, and shorter review clocks, but they also impose obligations: enhanced pharmacovigilance, risk management plans, lot release controls, and timely confirmatory trials. Decisions rely heavily on high-quality Phase I–III data, immunogenicity readouts that are reasonably likely to predict protection, and robust CMC packages that assure consistent quality for large-scale supply. A well-orchestrated regulatory strategy—scoped early and updated through parallel scientific advice—reduces rework and inspection risk; see practical regulatory planning checklists at PharmaRegulatory.in.

What the Major Programs Offer: FDA vs EMA vs WHO (At a Glance)

Although terminology differs, the goal is similar: expedite access while preserving scientific rigor. In the US, Fast Track facilitates frequent interactions and rolling review for serious conditions; Breakthrough Therapy adds intensive guidance when preliminary clinical evidence suggests substantial improvement; Priority Review shortens the review clock for applications with significant potential advances; and Accelerated Approval allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit, subject to confirmatory trials. In the EU, PRIME offers early, enhanced support for medicines addressing an unmet need, Accelerated Assessment shortens the CHMP evaluation timeline, and Conditional Marketing Authorization permits approval with less complete data when benefits outweigh risks and additional data will be provided post-authorization. WHO’s Emergency Use Listing (EUL) supports access in global health emergencies by assessing quality, safety, and performance to guide procurement by UN agencies and countries.

Illustrative Comparison of Accelerated Vaccine Pathways (Summary)
Jurisdiction Program What It Does Evidence Standard Key Sponsor Obligations
US FDA Fast Track / Breakthrough Rolling review; frequent advice; senior-level guidance Serious condition; nonclinical/clinical rationale; preliminary clinical signal (Breakthrough) Agreed development plan; timely safety updates; robust CMC controls
US FDA Priority Review / Accelerated Approval 6-month review clock; approval on surrogate reasonably likely to predict benefit Validated/credible surrogate (e.g., neutralizing antibody); strong totality of evidence Confirmatory trial(s) post-approval; enhanced PV and labeling updates
EMA PRIME / Accelerated Assessment Early support; shortened CHMP timetable Unmet need; major therapeutic advantage; high-quality development plan Milestone data packages; iterative scientific advice; GMP/GDP readiness
EMA Conditional Marketing Authorization Approval with less complete data when benefits outweigh risks Positive benefit–risk; plan to provide comprehensive data post-approval Specific obligations (SOBs); annual renewals; PASS/PAES as required
WHO Emergency Use Listing (EUL) Time-limited listing to facilitate global procurement during emergencies Quality, safety, performance dossier; risk management and manufacturing plan Ongoing data submissions; PV commitments; manufacturing consistency

Despite different routes, the constant theme is pre-specified commitments. Sponsors must maintain state-of-control manufacturing, rigorous clinical conduct, and transparent documentation. For high-level FDA references on vaccines and expedited programs, consult the agency’s public resources at fda.gov.

Evidence Packages and Surrogate Endpoints: Making “Reasonably Likely” Defensible

Accelerated and conditional approvals often hinge on immune surrogates—neutralizing antibody titers (e.g., ID50), binding IgG ELISA GMTs, or cell-mediated responses—that are reasonably likely to predict clinical benefit. To keep decisions defensible, the bioanalytical foundation must be fit-for-purpose and meticulously documented. Define assay performance in the lab manual and SAP: typical ELISA parameters might include LLOQ 0.50 IU/mL, ULOQ 200 IU/mL, LOD 0.20 IU/mL, precision ≤15%. For a pseudovirus neutralization assay, report a validated range of 1:10–1:5120 with values <1:10 imputed as 1:5. Pre-specify seroconversion (e.g., ≥4-fold rise) and responder criteria (e.g., ID50 ≥1:40) and define how out-of-range values are handled.

Statistical plans should connect immune readouts to plausible protection: correlation analyses, threshold modeling (e.g., hazard reduction per 2× rise in ID50), and sensitivity analyses for missingness and intercurrent events (receipt of non-study vaccines). If bridging from adults to adolescents, align with immunobridging principles and multiplicity control. Crucially, accelerated approval requires confirmatory trials designed and initiated without delay; these may be event-driven efficacy studies, large real-world effectiveness analyses, or immunobridging plus epidemiologic confirmation depending on pathogen epidemiology.

CMC Readiness Under Acceleration: Comparability, PDE/MACO, and Supply Integrity

Acceleration magnifies CMC scrutiny. Regulators will ask whether commercial-scale lots are comparable to clinical material and whether control strategy and release methods are validated. Include clear comparability protocols (e.g., antigen content, potency assays, particle size for mRNA/LNPs) and reference supportive toxicology. While clinical teams don’t compute manufacturing toxicology, citing PDE and MACO examples demonstrates end-to-end risk awareness and supports ethics reviews. For instance, a residual solvent PDE could be 3 mg/day, and a cleaning validation MACO surface limit may be 1.0–1.2 µg/25 cm2 for a process impurity. Present stability data supporting intended shelf life and temperature excursions; maintain cold-chain accountability (2–8 °C or −20/−80 °C as appropriate) with continuous monitoring and alarm management.

Illustrative CMC Readiness Checklist (Dummy)
Area Example Evidence Accelerated Focus
Comparability Clinical vs commercial lot potency and impurity profiles Predefined acceptance bands; bridging stability
Analytical Validity Potency assay precision ≤10%; LOD/LOQ defined Phase-appropriate validation with lifecycle plan
Cleaning MACO ≤1.0 µg/25 cm2 Campaign changeover strategy; swab recovery
Toxicology PDE example 3 mg/day residual Justification in risk assessments and QRM

Operational Execution: Monitoring, Documentation, and Inspection Readiness

Expedited timelines compress activities but never relax GxP. Use risk-based monitoring (central + targeted on-site) keyed to KRIs such as missing endpoint swabs, out-of-window visits, and drug accountability gaps. Establish a DSMB with rapid cadence, pre-declared pausing rules (e.g., any related anaphylaxis; ≥5% Grade 3 systemic AEs within 72 h in any arm), and clear unblinding procedures for safety emergencies. The Trial Master File (TMF) must be contemporaneously filed—protocol/SAP versions, IB updates, DSMB minutes, and data standards—because accelerated programs attract early inspections.

Illustrative Expedited Timeline (Dummy)
Milestone Target (Weeks) Dependencies
Pre-Submission Meeting T-24 Briefing book; CMC high-level plan
Rolling Module 2/3 Start T-20 Validated critical assays; stability update
Topline Phase III T-8 DB lock; SAP outputs
Marketing Application (Accelerated/Conditional) T-0 QA sign-off; PV plan; supply readiness

Document every key decision (e.g., surrogate selection, pausing rules) in signed minutes; align labeling text to evidence and risk language. After authorization, execute PASS/confirmatory trials and maintain transparent safety communications.

Case Study (Hypothetical): PRIME + Conditional Approval with Surrogate Immunogenicity

A protein-subunit vaccine for Pathogen X receives EMA PRIME based on compelling Phase IIb immunogenicity and safety. A pivotal Phase III immunobridging study shows ELISA GMT 1,850 (LLOQ 0.50 IU/mL; ULOQ 200 IU/mL; LOD 0.20 IU/mL) and neutralization ID50 responder rate 92% (values <1:10 set to 1:5). With an ongoing event-driven efficacy trial still accruing, the CHMP grants Conditional Marketing Authorization with specific obligations: (1) deliver 6-month and 12-month efficacy readouts; (2) complete a pediatric immunobridging cohort; (3) enhance myocarditis AESI surveillance with predefined observed/expected analyses. The sponsor’s PV plan integrates active surveillance in two national EHR networks and a global periodic safety report schedule. Confirmatory efficacy meets success criteria at 10 months, converting to a standard authorization and updating labeling. Throughout, CMC comparability is demonstrated as commercial lots replace late-phase clinical batches, with MACO ≤1.0 µg/25 cm2 and PDE examples referenced in risk assessments.

]]> WHO Guidelines for Clinical Trials and Global Drug Approvals: A Complete Overview https://www.clinicalstudies.in/who-guidelines-for-clinical-trials-and-global-drug-approvals-a-complete-overview-2/ Fri, 09 May 2025 15:36:23 +0000 https://www.clinicalstudies.in/?p=1086 Read More “WHO Guidelines for Clinical Trials and Global Drug Approvals: A Complete Overview” »

]]>
WHO Guidelines for Clinical Trials and Global Drug Approvals: A Complete Overview

Comprehensive Guide to WHO Guidelines for Clinical Trials and Global Drug Approvals

The World Health Organization (WHO) plays a crucial role in shaping global standards for clinical trials, drug approvals, and regulatory convergence. Although the WHO itself does not directly approve commercial drug products, its guidelines influence national regulations, support public health initiatives, and facilitate international collaboration to ensure access to safe, effective, and high-quality medicines worldwide.

Introduction to WHO Guidelines

Established in 1948, the WHO serves as the leading international authority on public health. Through its normative guidelines, technical reports, and global programs, WHO sets scientific and ethical standards for clinical research, product evaluation, vaccine prequalification, and emergency health responses. WHO’s guidance supports regulatory authorities, researchers, and sponsors in achieving consistency, quality, and equity across healthcare systems globally.

What are WHO Guidelines?

WHO guidelines consist of technical documents, codes of practice, and standards designed to guide the conduct of clinical trials, drug development, regulatory inspections, pharmacovigilance, and health emergencies. These guidelines promote ethical research practices, harmonize regulatory frameworks, and support access to essential medicines, especially in low- and middle-income countries (LMICs).

Key Components / Types of WHO Regulatory Guidelines

  • Good Clinical Practice (GCP) Guidelines: Ethical and scientific quality standards for designing, conducting, and reporting trials involving human subjects.
  • WHO Prequalification (PQ) Program: Assessment of the quality, safety, and efficacy of medicines, vaccines, and diagnostics for UN procurement and public health programs.
  • Ethical Guidelines for Health-Related Research: Principles ensuring the dignity, rights, safety, and well-being of research participants.
  • Emergency Use Listing (EUL): Rapid assessment mechanism for unlicensed products needed during public health emergencies, such as pandemics.
  • Pharmacovigilance and Post-Market Surveillance: Systems and frameworks for monitoring product safety after approval and during widespread use.

How WHO Guidelines Work (Step-by-Step Guide)

  1. Development of Normative Guidance: WHO convenes expert committees to create evidence-based guidelines on clinical research, product evaluation, and regulatory practices.
  2. Publication of Technical Reports and Manuals: Dissemination of official guidance documents to member states and stakeholders.
  3. Implementation by National Authorities: Countries adopt or adapt WHO guidelines to strengthen their local regulatory frameworks and healthcare systems.
  4. Prequalification (PQ) Process: Manufacturers seeking WHO PQ submit dossiers and undergo inspections and evaluations based on WHO standards.
  5. Monitoring and Updates: WHO continually revises guidelines based on emerging scientific evidence and public health needs.

Advantages and Disadvantages of WHO Guidelines

Advantages:

  • Promote ethical research practices and human subject protection globally.
  • Facilitate regulatory harmonization and capacity building among member states.
  • Enable access to high-quality, affordable medicines and vaccines in underserved regions.
  • Strengthen global responses to pandemics, epidemics, and public health emergencies.

Disadvantages:

  • WHO guidelines are non-binding; implementation depends on national governments.
  • Resource constraints may limit the capacity of some countries to fully adopt WHO standards.
  • Prequalification processes can be lengthy for manufacturers unfamiliar with WHO requirements.
  • Updates to technical guidance may lag behind rapidly evolving scientific innovations.

Common Mistakes and How to Avoid Them

  • Misinterpretation of Non-Binding Status: Recognize that while not mandatory, WHO guidelines often become de facto standards internationally.
  • Inadequate Preparation for Prequalification: Manufacturers should thoroughly understand WHO PQ technical requirements before submission.
  • Non-Compliance with GCP Standards: Ensure that clinical trials align with both national regulations and WHO-recommended practices.
  • Poor Pharmacovigilance Planning: Integrate proactive safety monitoring systems as required by WHO frameworks post-approval.
  • Failure to Engage with Regulatory Convergence Initiatives: Participate in harmonization efforts (e.g., ICH, WHO initiatives) to streamline global regulatory pathways.

Best Practices for Navigating WHO Guidelines

  • Engage Early with WHO Programs: For manufacturers, seek early technical advice if aiming for prequalification or emergency listing.
  • Implement Robust Quality Management Systems: Align manufacturing and clinical research processes with WHO standards to facilitate approvals.
  • Stay Updated on WHO Guidance: Monitor updates to technical documents and adapt internal practices accordingly.
  • Collaborate with Regulatory Networks: Leverage WHO-supported initiatives like the International Coalition of Medicines Regulatory Authorities (ICMRA).
  • Participate in WHO-Led Trainings and Workshops: Enhance capacity building, especially for regulatory professionals in emerging markets.

Real-World Example or Case Study

Case Study: WHO Emergency Use Listing for COVID-19 Vaccines

During the COVID-19 pandemic, WHO granted Emergency Use Listings (EULs) for vaccines such as Pfizer-BioNTech’s Comirnaty, AstraZeneca’s Vaxzevria, and Sinopharm’s BBIBP-CorV. EUL enabled rapid procurement by COVAX and global access to vaccines, particularly for LMICs, highlighting the critical role of WHO in coordinating global public health responses during emergencies.

Comparison Table: WHO Prequalification vs. WHO Emergency Use Listing

Aspect Prequalification (PQ) Emergency Use Listing (EUL)
Objective Assessment for procurement by UN agencies Rapid assessment during public health emergencies
Scope Medicines, vaccines, diagnostics Primarily vaccines and diagnostics
Evaluation Process Full review of quality, safety, efficacy Preliminary review based on available data
Duration Months to years Weeks to months
Post-Approval Monitoring Ongoing monitoring and requalification Continued data submission required

Frequently Asked Questions (FAQs)

Does WHO approve drugs for global marketing?

No, WHO does not approve drugs for commercial marketing but provides prequalification and guidance to support national regulatory authorities and UN procurement agencies.

What is WHO GCP?

WHO Good Clinical Practice (GCP) guidelines ensure that trials are ethically conducted, scientifically valid, and that participant rights are protected globally.

Can WHO guidelines be enforced by law?

No, WHO guidelines are non-binding unless adopted into national laws by individual countries.

What is the role of WHO Prequalification?

Prequalification assures the quality, safety, and efficacy of medicines and vaccines for procurement by UN agencies and global public health initiatives.

How does WHO support regulatory convergence?

WHO fosters harmonization of regulatory practices across regions through initiatives like collaborative registration procedures, ICH partnerships, and capacity building programs.

Conclusion and Final Thoughts

WHO guidelines serve as the backbone of ethical clinical research, regulatory harmonization, and global access to essential medicines. For sponsors, regulators, and researchers, understanding and adhering to WHO standards can facilitate faster access to markets, strengthen public health outcomes, and contribute to global healthcare equity. By actively engaging with WHO programs and aligning with evolving global standards, stakeholders can drive innovation and improve patient care worldwide. For comprehensive updates on global regulatory affairs and clinical research guidelines, visit clinicalstudies.in.

]]>